Márk Plander
Márk Plander publishes mostly in Genetics, Hematology and Pathology and Forensic Medicine, on topics such as Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment and Multiple Myeloma Research and Treatments.
- World rank
- #5,094,221 of 7,710,434 ranked researchers
- Rank in Hungary
- #12,605 of 25,218
- Works
- 55
- Citations
- 640
- Citations per work
- 11.6
What does Márk Plander research?
Márk Plander's work is mostly in Medicine (64%), Immunology and Microbiology (9%), Biochemistry, Genetics and Molecular Biology (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences3563.7%
- Medicine3563.7%
- Everything else1221.7%
- Life Sciences814.6%
- 1Genetics22% of their works
- 2Hematology17% of their works
- 3Pathology and Forensic Medicine16% of their works
- 4Oncology9% of their works
- 5Immunology9% of their works
- 6Molecular Biology6% of their works
Research topics
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- CNS Lymphoma Diagnosis and Treatment
Which keywords describe Márk Plander's research?
The keywords of their largest research topics: Rituximab, Prognostic Factors, Chronic Lymphocytic Leukemia, Genomic Aberrations, Classification, Lymphoma, Prognostic Scoring System and Diagnosis Criteria.
- PROTACs
- BET Bromodomains
- AML
- Myelofibrosis
- Genetic Mutations
- Diagnosis Criteria
- Lymphoma
- Genomic Aberrations
- Prognostic Factors
- Rituximab
- Chronic Lymphocytic Leukemia
- Classification
- Prognostic Scoring System
- International Myeloma Working Group
- JAK2 Mutation
- Primary Immunodeficiency
- Acute Myeloid Leukemia
- Chemotherapy
- Primary CNS Lymphoma
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Rituximab432 topics
- Prognostic Factors292 topics
- Chronic Lymphocytic Leukemia221 topic
- Genomic Aberrations221 topic
- Classification211 topic
- Lymphoma211 topic
- Prognostic Scoring System122 topics
- Diagnosis Criteria111 topic
- International Myeloma Working Group111 topic
- Genetic Mutations81 topic
- JAK2 Mutation81 topic
- Myelofibrosis81 topic
- Primary Immunodeficiency81 topic
- AML71 topic
- Acute Myeloid Leukemia71 topic
- BET Bromodomains41 topic
- Chemotherapy41 topic
- PROTACs41 topic
- Primary CNS Lymphoma41 topic
Where does Márk Plander work?
Márk Plander's main affiliation in the publication record is Markusovszky Egyetemi Oktatókórház, Hungary.
How many publications and citations does Márk Plander have?
OpenAlex counts 55 works and 640 citations for Márk Plander, an h-index of 12, ranking #5,094,221 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Márk Plander. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.